In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates

Abstract

The antibacterial effectiveness of eravacycline was compared with various antibiotics used in Acinetobacter therapy against multidrug-resistant (MDR) Acinetobacter baumannii strains. Antibacterial susceptibility studiea was achieved by the broth microdilution method against 52 non-duplicate, A. baumanniii strains to eravacycline, tobramycin, levofloxacin, cefepime, meropenem, and colistin. Eravacycline presented greater action than the comparators of the other group, cefepime, colistin, levofloxacin, and tobramycin. While the MIC50/90 values of eravacycline were 8/16 mg/ L and those for tobramycin, levofloxacin, cefepime, meropenem, and colistin were found 256/>256, 64/ >256, 256/ >256, 128/>256, and 0.5/256 mg/L, respectively. As a result, the present study showed that eravacycline was a potent effective antibiotic against MDR A. baumannii. Eravacycline could be an effective new alternative for use in particular, for the treatment of this problematic organism.